☆ 4.7 Meeting Abstract

Randomized phase 2 study of nivolumab (nivo) plus either standard or reduced dose bevacizumab (bev) in recurrent glioblastoma (rGBM).

JOURNAL OF CLINICAL ONCOLOGY (2021)

主要评分表示论文的整体质量水平。次要评分独立反映论文的优点或缺点。

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now